Psychological Impact of Melanoma, How to Detect, Support and Help
Incidence of melanoma is increasing every year. A few years ago, we could not speak about long term survivors with melanoma. Chemotherapy did not give a good effect in the past. Metastasis occurred very rapidly, and the progression of melanoma was very fast. But now, with new forms of therapy, especially immunotherapy and target therapy, for the first time, we have long-time survivors. For the prognosis of melanoma, the most important is the stage in which melanoma is detected. For all dermatologists, it is very important to be aware of the psychological impact of melanoma on patients. Dermatologists should recognise psychological disorders. Several different scales can be used for the detection of depression and anxiety â€“ some of them are completed by researchers, some of them are completed by patients, and also, we have combined scales. The need for adequate social and family support as well as psychological help to achieve better coping with illness is necessary. Learning techniques to overcome fear and stress would help in better functioning of all affected, regardless of the stage of the disease. The most severe cases of anxiety and depression, in addition to psychotherapeutic interventions, should also be considered medication therapy.
Plum Analytics Artifact Widget Block
Vojvodic A, Dedic G. Depression, anxiety and quality of life in patients with melanoma. VSP, 2018. https://doi.org/10.2298/VSP180414185V
Vojvodic A, Dedic G. Quality of Life and Anxiety in Military Personnel. SJECR, 2017.
Lotti T, Bruscino N, Hercogova J, de Giorgi V. Controversial issues on melanoma. Dermatol Ther. 2012; 25(5):458-62. https://doi.org/10.1111/j.1529-8019.2012.01524.x PMid:23046025
Campolmi E, et al. Melanoma diagnosis: traumatic impact of the event on the patient. G Ital Dermatol Venereol. 2019.
de Giorgi V, Gori A, Grazzini M, Rossari S, ScarfÃ¬ F, Corciova S, Verdelli A, Lotti T, Massi D. Estrogens, estrogen receptors and melanoma. Expert Rev Anticancer Ther. 2011;11(5):739-47. https://doi.org/10.1586/era.11.42 PMid:21554049
De Giorgi V, Grazzini M, Gandini S, Benemei S, Lotti T, Marchionni N, Geppetti P. Treatment with Î²-blockers and reduced disease progression in patients with thick melanoma. Arch Intern Med. 2011; 171(8):779-81. https://doi.org/10.1001/archinternmed.2011.131 PMid:21518948
Rogiers A, Boekhout A, Schwarze JK, Awada G, Blank CU, Neyns B. Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors. J Oncol. 2019. https://doi.org/10.1155/2019/5269062 PMid:31182961 PMCid:PMC6512024
Heino PJ, MyllÃ¤ri PH, Jahkola TA, Sintonen H, Luoma ML, RÃ¤sÃ¤nen P, Roine RP. Long-Term Quality of Life of Melanoma Survivors Is Comparable to that of the General Population. Anticancer Res. 2019; 39(5):2633-2640. https://doi.org/10.21873/anticanres.13387 PMid:31092462
O'Reilly A, et al. An immunotherapy survivor population: health-related quality of life and toxicity in patients with metastatic melanoma treated with immune checkpoint inhibitors. Support Care Cancer. 2019. https://doi.org/10.1007/s00520-019-04818-w
Dieng M, et al. Psychoeducational Intervention to Reduce Fear of Cancer Recurrence in People at High Risk of Developing Another Primary Melanoma: Results of a Randomized Controlled Trial. J Clin Oncol. 2016; 34(36):4405-4414. https://doi.org/10.1200/JCO.2016.68.2278 PMid:27998215
Fioranelli M, Roccia MG, Pastore C, Aracena CJ, Lotti T. Completion dissection or observation for sentinel-node metastasis in melanoma. Dermatol Ther. 2017; 30(6). https://doi.org/10.1111/dth.12544 PMid:28836714
Vaccaro M, Lentini M, Lotti J, Fioranelli M, Roccia MG, Lotti T, Guarneri C. Hard to face: cutaneous malignant melanoma. J Biol Regul Homeost Agents. 2017; 31(2):53-55.
Chokoeva AA, Tchernev G, Wollina U, Lotti T. Cutaneous melanoma: how to improve the quality of diagnosis and treatment - a regional experience. Dermatol Ther. 2015; 28(6):344-5. https://doi.org/10.1111/dth.12278 PMid:26279288
Vojvodic A, Dedic G, Djukic-Dejanovic S. Defense mechanisms and quality of life in military personnel with burnout syndrome. VSP. 2019. 76(3):298-306. https://doi.org/10.2298/VSP170304114V
Smith K. Mental health: a world of depression. Nature. 2014; 515(7526):181. https://doi.org/10.1038/515180a PMid:25391942
Tas F, Karabulut S, Guveli H, Kurul S, Erturk K, Guveli M, Kinik H. Assessment of Anxiety and Depression Status in Turkish Cutaneous Melanoma Patients. Asian Pac J Cancer Prev. 2017; 18(2):369-373.
Brown SL, Hope-Stone L, Heimann H, Damato B, Salmon P. Predictors of anxiety and depression 2 years following treatment in uveal melanoma survivors. Psychooncology. 2018; 27(7):1727-1734. https://doi.org/10.1002/pon.4715 PMid:29601654
Miniati M, et al. Quality of Life, Depression, and Anxiety in Patients with Uveal Melanoma: A Review. J Oncol. 2018:5253109. https://doi.org/10.1155/2018/5253109 PMid:29755525 PMCid:PMC5883983
Copyright (c) 2019 Aleksandra Vojvodic, Tatjana Vlaskovic-Jovicevic, Petar Vojvodic, Jovana Vojvodic, Mohamad Goldust, Zorica Peric-Hajzler, Dusica Matovic, Goran Sijan, Nenad Stepic, Van Thuong Nguyen, MIchael Tirant, Uwe Wollina, Torello Lotti, Massimo Fioranelli (Author)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All rights reserved.